{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:54:30Z","timestamp":1790045670143,"version":"4.0.1"},"reference-count":36,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R\u2010Pola) in patients with relapsed\/refractory (R\/R) large B\u2010cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun\u2010Pola), with &gt;\u20092\u2009years of follow\u2010up. Patients with R\/R LBCL and \u2265\u20091 prior line of therapy were randomized to receive Mosun\u2010Pola or R\u2010Pola. Mosunetuzumab was administered subcutaneously with Cycle (C) 1 step\u2010up dosing (5\/45\/45\u2009mg) then 45\u2009mg on C2 Day (D) 1\u2013C8D1 (21\u2010day\u2009cycles). Polatuzumab vedotin (1.8\u2009mg\/kg) was given intravenously (IV) on D1 of C1\u20136. Rituximab IV (375\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) was given on D1 of C1\u20138. Primary endpoint was best objective response rate (ORR). As of November 15, 2024, 80 patients had been enrolled (Mosun\u2010Pola,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200940; R\u2010Pola,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200940). Best ORR was 77.5% (95% confidence interval [CI] 61.6\u201389.2) for Mosun\u2010Pola and 50.0% (95% CI: 33.8\u201366.2) for R\u2010Pola; complete response (CR) rates were 55.0% (95% CI: 38.5\u201370.7) and 35.0% (95% CI: 20.6\u201351.7), respectively. Median progression\u2010free survival was 25.4\u2009months for Mosun\u2010Pola and 6.4\u2009months for R\u2010Pola (hazard ratio [HR] 0.47); median overall survival was not reached and 25.5\u2009months (HR: 0.78), respectively. Cytokine release syndrome occurred in 12.5% of Mosun\u2010Pola\u2010treated patients (all Grade 1\/2). Fixed\u2010duration Mosun\u2010Pola demonstrated benefit across all efficacy endpoints compared with R\u2010Pola in patients with R\/R LBCL. These findings are consistent with the observed benefit of Mosun\u2010Pola for patients with R\/R LBCL in the global Phase III SUNMO study (NCT05171647).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link>\n                    number: NCT03671018\n                  <\/jats:p>","DOI":"10.1002\/ajh.70403","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:31:21Z","timestamp":1781260281000},"page":"2177-2189","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Randomized Phase\n                    <scp>II<\/scp>\n                    Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B\u2010Cell Lymphoma"],"prefix":"10.1002","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-6238","authenticated-orcid":false,"given":"Julio C.","family":"Chavez","sequence":"first","affiliation":[{"name":"Department of Malignant Hematology Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bastos\u2010Oreiro","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital General Universitario Gregorio Mara\u00f1\u00f3n  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"Clinical Lymphoma Program, Perlmutter Cancer Center at NYU Langone Health  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"Division of Hematology Sylvester Comprehensive Cancer Center, University of Miami Health System  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1071","authenticated-orcid":false,"given":"Nirav","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medical College of Wisconsin  Milwaukee Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[{"name":"Division of Hematology Jewish General Hospital  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[{"name":"Department of Medicine The Warren Alpert Medical School, Brown University  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-151X","authenticated-orcid":false,"given":"Seema","family":"Naik","sequence":"additional","affiliation":[{"name":"Department of Medicine Penn State Cancer Institute  Hershey Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-6136","authenticated-orcid":false,"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology and Blood Disorders Levine Cancer Institute\/Atrium Health  Charlotte North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Pham","sequence":"additional","affiliation":[{"name":"Hoffmann\u2010La Roche Ltd.  Mississauga Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wei","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Batlevi","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"To","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahib","family":"Ead","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Makadia","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elicia","family":"Penuel","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jing","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center  Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577189"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00997-w"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2321648"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"e_1_2_12_8_1","unstructured":"US Food and Drug Administration \u201cLunsumio: FDA Prescribing Information \u201d(2025) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761263s005lbl.pdf."},{"key":"e_1_2_12_9_1","unstructured":"European Medicines Agency \u201cLunsumio: Summary of Product Characteristics \u201d(2024) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lunsumio."},{"key":"e_1_2_12_10_1","unstructured":"US Food and Drug Administration \u201cPolivy: FDA Prescribing Information \u201d(2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761121s008lbl.pdf."},{"key":"e_1_2_12_11_1","unstructured":"European Medicines Agency \u201cPolivy: Summary of Product Characteristics \u201d(2025) https:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/2022\/20220524155625\/anx_155625_en.pdf."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02726-5"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194612"},{"key":"e_1_2_12_14_1","unstructured":"F. Hoffmann\u2010La Roche Ltd \u201cEuropean Commission Approves Roche's Lunsumio Subcutaneous for Relapsed or Refractory Follicular Lymphoma \u201d(2025) https:\/\/www.roche.com\/media\/releases\/med\u2010cor\u20102025\u201011\u201019."},{"key":"e_1_2_12_15_1","unstructured":"US FoodandDrug Administration \u201cLunsumio Velo: FDA Prescribing Information \u201d(2025) https:\/\/www.gene.com\/download\/pdf\/lunsumio_velo_prescribing.pdf."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194581"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147937"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01957"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00921-6"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009260"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70128-2"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283480"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02572-5"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020854"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)02300-6"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148359"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026830"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70403","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70403","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:19:33Z","timestamp":1785583173000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/ajh.70403"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70403","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"2026-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}